| 1 Morning PEFR after treatment |
1 |
|
Std. Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 1.1 Adults |
1 |
17 |
Std. Mean Difference (IV, Fixed, 95% CI) |
0.38 [‐0.58, 1.34] |
| 2 FEV1 after treatment (% predicted) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 2.1 Adults |
1 |
45 |
Mean Difference (IV, Fixed, 95% CI) |
1.70 [‐8.04, 11.44] |
| 3 Symptom scores (parallel studies) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 3.1 Adults |
1 |
17 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 4 FEV1 at follow‐up: pooled cross‐over data (% predicted) |
2 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 4.1 Within 4 weeks of start of treatment |
2 |
40 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [‐15.13, 15.13] |
| 4.2 5 to 12 weeks after start of treatment |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 5 FVC after treatment: pooled cross‐over (l) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 6 FEV1 at follow‐up: pooled cross‐over data (Change from baseline) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 6.1 Within 4 weeks of start of treatment |
1 |
50 |
Mean Difference (IV, Fixed, 95% CI) |
‐5.40 [‐26.53, 15.73] |
| 6.2 5 to 12 weeks after start of treatment |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 7 FEV1 after treatment: pooled cross‐over data |
2 |
84 |
Std. Mean Difference (IV, Fixed, 95% CI) |
0.12 [‐0.31, 0.55] |
| 7.1 Adults |
2 |
84 |
Std. Mean Difference (IV, Fixed, 95% CI) |
0.12 [‐0.31, 0.55] |
| 7.2 Children |
0 |
0 |
Std. Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 8 Perceived improvement in general well‐being after treatment (parallel studies) |
2 |
56 |
Risk Ratio (M‐H, Random, 95% CI) |
1.13 [0.51, 2.51] |
| 8.1 Adults |
2 |
56 |
Risk Ratio (M‐H, Random, 95% CI) |
1.13 [0.51, 2.51] |
| 8.2 Children |
0 |
0 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
| 9 Symptom scores cross‐over studies |
1 |
|
Std. Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 9.1 Adults |
1 |
46 |
Std. Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 9.2 Children |
0 |
0 |
Std. Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 10 Symptom scores (crossover studies ‐ change from baseline) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 10.1 Adults |
1 |
50 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 10.2 Children |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 11 Symptom scores |
1 |
|
Symptom scores (Fixed, 95% CI) |
Subtotals only |
| 11.1 Adults |
1 |
|
Symptom scores (Fixed, 95% CI) |
‐1.71 [‐4.65, 1.23] |
| 11.2 Children |
0 |
|
Symptom scores (Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 12 Medication usage |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 12.1 Adults |
1 |
46 |
Mean Difference (IV, Fixed, 95% CI) |
‐1.40 [‐9.24, 6.44] |
| 12.2 Children |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 13 Medication usage |
1 |
|
ß‐agonist (Fixed, 95% CI) |
Subtotals only |
| 13.1 Adults |
1 |
|
ß‐agonist (Fixed, 95% CI) |
0.1 [‐0.88, 1.08] |
| 13.2 Children |
0 |
|
ß‐agonist (Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 14 Medication usage (change from baseline) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 14.1 Adults |
1 |
50 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 14.2 Children |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 15 Quality of life follow‐up |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 15.1 Adults |
1 |
46 |
Mean Difference (IV, Fixed, 95% CI) |
‐11.0 [‐32.11, 10.11] |
| 15.2 Children |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
